research
Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings
- Publication date
- 2 August 2013
- Publisher
- 'Oxford University Press (OUP)'